U.S. markets close in 2 hours 19 minutes
  • S&P 500

    3,443.53
    +0.41 (+0.01%)
     
  • Dow 30

    28,259.70
    -49.09 (-0.17%)
     
  • Nasdaq

    11,515.03
    -1.46 (-0.01%)
     
  • Russell 2000

    1,608.18
    -9.53 (-0.59%)
     
  • Crude Oil

    39.92
    -1.78 (-4.27%)
     
  • Gold

    1,928.80
    +13.40 (+0.70%)
     
  • Silver

    25.25
    +0.27 (+1.06%)
     
  • EUR/USD

    1.1871
    +0.0042 (+0.36%)
     
  • 10-Yr Bond

    0.7990
    +0.0020 (+0.25%)
     
  • GBP/USD

    1.3153
    +0.0206 (+1.59%)
     
  • USD/JPY

    104.5200
    -0.9500 (-0.90%)
     
  • BTC-USD

    12,831.81
    +1,774.81 (+16.05%)
     
  • CMC Crypto 200

    257.24
    +12.35 (+5.04%)
     
  • FTSE 100

    5,776.50
    -112.72 (-1.91%)
     
  • Nikkei 225

    23,639.46
    +72.42 (+0.31%)
     

Misonix to Present at the Cantor Virtual Global Healthcare Conference

MISONIX, Inc.
·1 min read

FARMINGDALE, N.Y., Sept. 09, 2020 (GLOBE NEWSWIRE) -- Misonix, Inc. (Nasdaq: MSON), a provider of minimally invasive therapeutic ultrasonic medical devices and regenerative products that enhance clinical outcomes, today announced that it will be participating in the Cantor Virtual Global Healthcare Conference. Misonix Chief Executive Officer, Stavros Vizirgianakis, along with Joe Dwyer, Misonix Chief Financial Officer, will be making a virtual company presentation on Thursday, September 17th at 11:20 a.m. ET. Management will also be available to speak with institutional investors in one-on-one virtual meetings throughout the day.

If you have questions about Misonix or are interested in conducting a conference call or meeting with management, please contact the Company’s investor relations firm, JCIR, at (212) 835-8500 or via email at mson@jcir.com.

About Misonix, Inc.

Misonix, Inc. (Nasdaq: MSON) is a provider of minimally invasive therapeutic ultrasonic medical devices and regenerative tissue products. Its surgical team markets and sells BoneScalpel and SonaStar, which facilitate precise bone sculpting and removal of soft and hard tumors and tissue, primarily in the areas of neurosurgery, orthopedic, plastic and maxillo-facial surgery. The Company's wound team markets and sells TheraSkin, Therion, TheraGenesis and SonicOne to debride, treat and heal chronic and traumatic wounds in inpatient, outpatient and physician office sites of service. At Misonix, Better Matters! That is why throughout the Company’s history, Misonix has maintained its commitment to medical technology innovation and the development of products that radically improve outcomes for patients. Additional information is available on the Company's web site at www.misonix.com.

Contact:

Joe Dwyer

Norberto Aja, Jennifer Neuman

Chief Financial Officer

JCIR

Misonix, Inc.

212-835-8500 or mson@jcir.com

631-927-9113